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Abstract
Vascular endothelial growth factor (VEGF) was originally identified as an endothelial cell specific growth factor stimulating angiogenesis and vas-
cular permeability. Some family members, VEGF C and D, are specifically involved in lymphangiogenesis. It now appears that VEGF also has
autocrine functions acting as a survival factor for tumour cells protecting them from stresses such as hypoxia, chemotherapy and radiotherapy. The
mechanisms of action of VEGF are still being investigated with emerging insights into overlapping pathways and cross-talk between other recep-
tors such as the neuropilins which were not previously associated with angiogenesis. VEGF plays an important role in embryonic development and
angiogenesis during wound healing and menstrual cycle in the healthy adult. VEGF is also important in a number of both malignant and non-malig-
nant pathologies. As it plays a limited role in normal human physiology, VEGF is an attractive therapeutic target in diseases where VEGF plays a
key role. It was originally thought that in pathological conditions such as cancer, VEGF functioned solely as an angiogenic factor, stimulating new
vessel formation and increasing vascular permeability. It has since emerged it plays a multifunctional role where it can also have autocrine pro-sur-
vival effects and contribute to tumour cell chemoresistance. In this review we discuss the established role of VEGF in angiogenesis and the under-
lying mechanisms. We discuss its role as a survival factor and mechanisms whereby angiogenesis inhibition improves efficacy of chemotherapy
regimes. Finally, we discuss the therapeutic implications of targeting angiogenesis and VEGF receptors, particularly in cancer therapy.
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Introduction
Vascular endothelial growth factor (VEGF) was
originally described as a homodimeric 34–42 kD
protein that increased vascular permeability in the
skin [1]. It was identified by partial purification
from the ascites fluid and cell culture supernatants
of a guinea-pig hepatocarcinoma cell line and
termed vascular permeability factor (VPF). VPF
was the most potent permeability enhancing factor
known and was responsible for the vascular hyper-
permeability and the accumulation of plasma-pro-
tein-rich fluid in solid and ascites tumours [1]. In
1989 Ferrara and Henzel identified a growth factor
for endothelial cells in conditioned medium from
bovine follicular pituitary cells and called it VEGF
[2]. This was subsequently sequenced and found to
be identical to VPF [3, 4]. VEGF is required for
growth and differentiation of endothelial cells [3].
In addition, it is chemotactic for monocytes, attract-
ing these cells into sites of inflammation and
tumours [5].
VEGF family and isoforms
The VEGF gene family consists of VEGF-A (here-
after referred to as VEGF), VEGF-B, VEGF-C,
VEGF-D, VEGF-E and placental growth factor
(PLGF). These glycoproteins belong to a structural
superfamily of growth factors which includes
PDGF. VEGF-A is mainly involved in angiogenesis
while VEGF-C and VEGF-D are involved in lym-
phangiogenesis. VEGF mediates its signals via high
affinity receptor tyrosine kinases which have struc-
tural and functional similarities to the platelet
derived growth factor (PDGF) family, suggesting
the VEGF and PDGF receptor sub families are evo-
lutionarily linked [6].The human VEGF-A gene is
organized into eight exons and alternative exon
splicing results in at least 5 different isoforms, the
more common isoforms consisting of 121, 145,
165, 189, 206 amino acids (termed VEGF121,
VEGF145 VEGF165, VEGF189, VEGF206, respec-
tively) (Fig. 1 and [7]). Other isoforms have also
been reported consisting of 148, 162 and 183 amino
acids (termed VEGF148, VEGF162, VEGF183) and a
more recently identified variant of VEGF165, which
is termed VEGF165b. The splice variants are distin-
guished by their heparin and heparin-sulfate bind-
ing ability. The amino acids encoded by exons 1-5
are conserved in all isoforms but alternative splic-
ing can occur in exons 6 and 7. These exons encode
2 heparin-binding domains, which influence recep-
tor binding and solubility. The isoforms that encode
this exon 6 are tightly bound to the cell surface
(VEGF145, VEGF189 VEGF206). The isoforms lack-
ing exon 6 are diffusible. VEGF165 which lacks
only exon 6 is moderately diffusible where as
VEGF121 lacks both exon 6 and 7 and is therefore
highly diffusible [8]. VEGF165 is the most predom-
inant isoform and is also the most potent in terms of
stimulating angiogenesis. It can bind to both hep-
arin and the extracellular matrix [9]. The more
recently identified splice variant VEGF165b has the
same number of amino acids as VEGF165 but 6
amino acids in the COOH terminal region usually
coded for by exon 8 are different. The COOH ter-
minal of VEGF165 is necessary for determining
mitogenic signaling, therefore changes in this
region are likely to influence function. The authors
termed this new open reading frame exon 9 [10].
Unlike the other VEGF isoforms, which stimulate
angiogenesis, VEGF165b is an endogenous inhibito-
ry form of VEGF, which decreases VEGF-induced
proliferation and migration of endothelial cells.
Although it can bind to VEGFR-2 (Flk-1/KDR)
VEGF165b binding does not result in receptor phos-
phorylation or activation of the downstream signal-
ing pathways [10].
VEGF-B is a highly basic heparin binding growth
factor, which is structurally similar to VEGF-A and
PLGF. It is highly abundant in tissues such as heart,
skeletal muscle and pancreas and may act in
paracrine fashion to regulate endothelial cell function
[11]. VEGF-B expression has been found in astrocy-
tomas [12] and squamous oral cancer [13]. High lev-
els of VEGF-B and C have been associated with
lymph node metastasis of colorectal cancer [14] but
its functional role in tumours has not been fully
investigated.
VEGF-C was isolated from the conditioned
medium of PC3 prostate cancer cells and identi-
fied as a specific activator of VEGF receptor 3
(VEGFR-3). VEGF-C binds VEGFR-3 and
induces tyrosine phosphorylation of VEGF recep-
tor 2 (VEGFR-2) and VEGFR-3 [15]. VEGF-D is
also a ligand for both VEGFR-2 and VEGFR-3.
Both VEGF-C and D are mitogenic for lymphatic
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endothelial cells and promotes lymphatic endothe-
lial cell survival via VEGFR-3 [16, 17, 18].
VEGF-C also induces hyperplasia of pre-existing
lymphatic vessels [19].
VEGF-E is the viral VEGF homologue encoded by
the Orf virus, which is structurally similar to VEGF-A.
VEGF-E binds to and activates VEGFR-2 but not
VEGFR-1 and is a potent stimulator of angiogenesis [20].
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Fig. 1 VEGF-A isoforms. There are at least 6 different isoforms of VEGF-A, which arise by alternative exon splic-
ing. VEGF165 is the most potent in terms of inducing angiogenesis whereas VEGF165b inhibits angiogenesis. All iso-
forms contain exons 1-5.
Fig. 2 VEGF receptors and their lig-
ands. The VEGF receptors Flt-1
(VEGFR-1), Flk-1/KDR (VEGFR-2),
Flt-4 (VEGFR-3), Neuropilin-1 and 2
(NRP-1,2) and the VEGF family
members they bind are shown .  Flt-1,
Flk-1/KDR and the NRPs play a role
in angiogenesis whereas Flt-4 is
involved in lymphangiogenesis. Flt-1,
Flk-1/KDR and Flt-4 all have tyrosine
kinase activity which mediates VEGF
signaling. However, the NRPs have
no tyrosine kinase domain and the
VEGF signaling pathway via NRPs is
currently unknown. 
VEGFR-1 VEGFR-2 and VEGFR-3
all have IgG domains.
The NRPs have an a1/a2 domain
b1/b2 domain       , C domain.
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VEGF receptors
VEGF receptors were initially identified on
endothelial cells. VEGF binds to the three receptor
tyrosine kinases, flt-1 (fms-like tyrosine kinase,
VEGFR-1), Flk-1/KDR (fetal liver kinase 1-
murine homologue/Kinase insert Domain contain-
ing Receptor-human homologue, VEGFR-2) and
flt-4 (VEGFR-3). VEGFR-1 and VEGFR-2 are
primarily found on the vascular endothelium
whereas VEGFR-3 is mostly found on the lym-
phatic endothelium. These receptors all have an
extracellular domain, a single transmembrane
region and a consensus tyrosine kinase sequence
interrupted by a kinase-insert domain [21, 22].
More recently neuropilin (NRP-1), originally
identified as a receptor for the semaphorin/col-
lapsin family of neuronal guidance mediators, was
shown to act as an isoform specific receptor for
VEGF165 (Fig. 2 and [23]).
VEGFR-1 (flt-1) is a 180 kD transmembrane
protein, which binds VEGF-A, PLGF and VEGF-B
[24]. It was originally cloned from a placental
cDNA library [21]. Alternative splicing produces a
shorter soluble form (soluble flt-1, sVEGFR-1)
which can act as an inhibitor of VEGF [25]. The
affinity of VEGFR-1 for VEGF is ten-fold higher
than VEGFR-2 but its tyrosine kinase activity is
ten-fold weaker than VEGFR-2. VEGFR-1 can
also act as a decoy receptor preventing VEGF
binding to the more mitogenic receptor VEGFR-2
[24]. In addition to endothelial cells, VEGFR-1 is
also expressed by monocytes, osteoblasts,
macrophages, pericytes, hematopoietic stem cells,
vascular smooth muscle cells and more recently
VEGFR-1 was identified on colorectal tumour
cells [26–29]. VEGF signaling has been shown to
occur in cells that solely express VEGFR-1, indi-
cating that it does have mitogenic properties and in
these cases sVEGFR-1 may act as the regulator for
VEGF activity by preventing VEGF binding to the
membrane bound VEGFR-1 receptor [30].
VEGFR-2 (KDR/flk-1) was first identified from a
human endothelial cell cDNA library [22]. It is a
230 kD glycoprotein and it binds VEGF, VEGF-C
and VEGF-D and has a lower affinity for VEGF
than VEGFR-1. However, VEGFR-2 is the prima-
ry mediator of VEGF signaling as demonstrated by
selective activation of either VEGFR-1 or VEGFR-
2. Using novel highly selective VEGF mutants
with substantially increased selectivity for either
VEGFR-1 or VEGFR-2, it was demonstrated that
VEGFR-2 is the primary mediator of VEGF sig-
naling [31]. In addition to endothelial cells,
hematopoietic stem cells, megakaryocytes, retinal
progenitor cells and vascular smooth muscle cells
express VEGFR-2. More recently, along with
VEGFR-1, VEGFR-2 has been identified on some
tumour cell lines, non-small cell lung carcinomas
(NSCLCs), breast, neuroblastoma and gastric can-
cer cells [6, 28, 32–34]. VEGFR-3 (flt-4) is a 170
kD glycosylated protein which was first cloned
from human erythroleukemia cells and placental
cDNA libraries [35]. It binds the full length and
mature forms of VEGF-C and is expressed in
embryonic endothelial cells but during develop-
ment its expression on blood vessels decreases and
becomes restricted to the lymphatic endothelium in
adult tissue [36].
Neuropilin-1 (NRP-1) was originally identified
on neuronal cells as a receptor for the class 3
semaphorins/collapsins family of neuronal guid-
ance mediators [37]. Endothelial cells also express
NRP-1 where it acts as an isoform specific recep-
tor for VEGF [38]. NRP-1 lacks an intracellular
tyrosine kinase domain and therefore must act in
conjunction with other receptors to mediate VEGF
signaling. NRP-1 can associate with both Flt-1 [39]
and Flk-1/KDR to transduce a signal [40]. Indeed
Flk-1/KDR interacts with NRP-1 to form a recep-
tor complex that can enhance binding of VEGF165
[41]. NRP-1 was shown to bind VEGF165 via the
exon 7 domain. Interestingly, VEGF was found to
bind to tumour cells which did not express
VEGFR-1 or VEGFR-2 [38] and it was subse-
quently found that these cells express NRPs. NRP-
1 expression was observed in some tumours and
originally thought to be exclusively expressed by
the tumour endothelium but more recently NRP-1
expression was identified on tumour cells such as
the MDA-MB-231 breast tumour cells, human
astrocytomas, neuroblastoma, lung, pancreatic,
gastric tumour cells and colon cancer cells
[42–49]. Neuropilin-2 (NRP-2) can also bind
VEGF, but like NRP-1 lacks a cytoplasmic signal-
ing domain. It can bind VEGF165 but not VEGF121
and unlike NRP-1 it can also bind VEGF145 [50].
NRP-2 can also bind the heparin binding form of
placental growth factor (PLGF) and can also inter-
act with VEGFR-1 [51].
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VEGF signaling
The main functions of VEGF are to promote sur-
vival, induce proliferation and enhance migration
and invasion of endothelial cells, which contribute
to angiogenesis. It regulates these functions by inter-
acting with its tyrosine kinase receptors and trans-
mitting signals to various down stream proteins.
Cell proliferation and gene expression
VEGF stimulates DNA synthesis and proliferation
via VEGFR-2 and extracellular-regulated kinase-1/2
(ERK1/2). Activation of ERK 1/2 is mediated by
Ras-Raf-MEK-ERK pathway (Fig. 3) [52, 53]. The
mitogen activated protein kinase (MAPK) pathway
is also implicated in cell proliferation in response to
VEGF. Evidence suggests that VEGFR-2 is the
receptor which mediates this, as VEGF can activate
MAPK in pancreatic aortic endothelial (PAE) cells
expressing VEGFR-2 where as cells expressing
VEGFR-1 are unable to activate MAPK [54].
Cell survival
Under stress conditions such as serum depletion,
VEGF binds to VEGFR-2, which activates the
phosphatidyl inositol kinase (PI3-Kinase) path-
way and Akt/protein kinase B (PKB) phosphory-
lation. Akt is a serine kinase involved in anti-
apoptotic signaling and it is sufficient to promote
survival of serum starved HUVEC. Using a PI3-K
inhibitor, wortmannin, abolishes Akt activation
and completely blocks VEGF mediated survival.
VEGF binding to VEGFR-1 does not activate this
pathway and is not involved in VEGF mediated
cell survival [55].
Integrins/cell adhesion receptors such as the
endothelium specific adhesion molecule αvβ3 also
play a role in VEGF signal transduction. The cell
adhesion molecule VE-Cadherin interacts with
VEGFR-2 forming a complex with β−catenin and
PI3-Kinase to promote cell survival. Disruption of
the VE-Cad gene in mice prevents endothelial cells
from responding to survival signals. VEGFR-1 has
no association with the VE-Cad complex [56].
Fig. 3 VEGF signaling via
VEGFR-2. VEGF plays a role in
cell survival, migration, and prolif-
eration of endothelial cells. VEGF
binding to VEGFR-2 initiates a
number of signaling cascades.
PLCγ; PKC: protein kinase C;
ERK: extracellular regulated
kinase; MAPK: mitogen activated
protein kinase; FAK: focal adhe-
sion kinase; PI3-K: phosphatidyl
inositol 3' kinase; Akt/PKB: pro-
tein kinase B.
Migration
The fact that VEGF acts as a chemo-attractant for
endothelial cells suggests it plays a role in migra-
tion and invasion. In addition to endothelial cells,
VEGF also stimulates migration of vascular smooth
muscle cells, monocytes, mononuclear phagocytes
and polymorphonuclear cells [8, 26] and migration
and invasion of some tumour cells such as breast
and leukemia. The VEGF receptors VEGFR-1 and
VEGFR-2 and the NRPs have all been implicated in
VEGF-mediated cell migration and invasion [32,
57–59]. In tumours, increased tumour cell migra-
tion and invasion facilitates tumour cell dissemina-
tion to secondary organs - metastasis.
VEGF induces cell migration by activating fac-
tors such as focal adhesion kinase (FAK) and
Paxillin and also via the PI3 Kinase/Akt pathway
(Fig. 3). FAK activation is mediated by the c-termi-
nal region of VEGF-R2 [60]. VEGF activation of
the p38/MAPK stress pathway is also implicated in
cell migration and p38 inhibitors decrease cell
migration [61]. Using VEGF mutants it was deter-
mined that only VEGFR-2 and not VEGFR-1 result-
ed in p38 phosphorylation suggesting that VEGFR-
2 is the main mediator of cell migration in endothe-
lial cells (HUVEC) [31]. Similarly, VEGFR-1 acti-
vation had no effect on migration of bovine aortic
endothelial cells [31, 62].
Receptor interaction
Along with initiating downstream effects, VEGF
receptors have been shown to interact with each
other in order to enhance signaling. Of special inter-
est is the signaling of the more novel VEGF recep-
tors, the neuropilins, which lack tyrosine kinase
activity and must therefore interact with other
receptors to transduce signaling. NRP-1 has been
shown to interact with both VEGFR-1 and VEGFR-
2, and NRP-2 forms complexes with VEGFR-1 [39,
40, 51]. NRP-1 can also act as a survival factor for
tumour cells that don’t express the other classic
VEGF receptors [42].
In neuronal cells, Neuropilins can form com-
plexes with the Plexin family to form functional
semaphorin 3A (Sema3A) receptors which can
transduce biological signals [63]. Plexins may also
be important in VEGF signaling in tumour cells,
which express NRPs but no VEGF receptor tyro-
sine kinases. Bachelder et al. saw expression of
Plexin-A1 and Sema3A on breast tumour cell lines
where NRP-1 was the only VEGF receptor and
identified a competitive relationship between
VEGF and Sema3A with respect to tumour cell
migration [64].
Gray et al. (2005) [65, 66] showed that over-
expressing NRP-1 in a pancreatic tumour cells line
(Panc-1) inhibited in vivo tumour growth and
decreased cell migration. They used a construct of
NRP-1, which was missing the VEGF/Sema3a
interacting domain as well as a full-length NRP-1
construct. Since they found the same results for
both constructs they established that these signals
are independent of VEGF and Sema3A. These
cells do not express the other classical VEGF
receptors or the NRP-1 co-receptor Plexin-A1.
Decreasing NRP-1 expression using siRNA,
increased tumour cell migration and in vivo
tumourgenicity. However they also showed in a
separate study that over-expression of NRP-1
increased chemo-resistance of the same cell line
where as down regulation of NRP-1 with siRNA
increased chemosensitivity [65, 66].
VEGF signaling mechanisms in tumour cells
with NRP as their sole VEGF receptor are not fully
understood. Different effects have been shown in
relation to NRP-1 expression and tumour outcome,
which may depend on the expression of its co-fac-
tors. Elucidation of the overlapping signaling path-
ways between neuronal and endothelial cells may
help to identify VEGF signaling mechanisms via
the neuropilins.
VEGF in embryogenesis
VEGF levels are critical in establishing a vascular
network during embryo development. If a single
VEGF allele is missing embryonic lethality in mice
occurs between day 11 and 12 most likely as a con-
sequence of defective vascularisation. A reduced
number of nucleated red blood cells within blood
islands and in the yolk sac were observed in these
VEGF mutant embryos [67]. 
The VEGF receptors also play a crucial role in
early development as targeted deletion of VEGFR-
1 in mice results in death at embryo day 8.5 due to
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a lack of the functional blood vessels [68].
Interestingly, when only the tyrosine kinase domain
was deleted leaving the transmembrane and extra-
cellular domains intact, the embryos developed nor-
mal blood vessels and survived. One explanation
might be that VEGFR-1 is an antagonist of VEGF
signaling rather than a signal transducer in embryo-
genesis [69]. A soluble form of VEGFR-1 (sVEGFR-
1) can form a heterodimeric complex with VEGFR-2
preventing VEGF binding o the more mitogenic
VEGFR-2 thus inhibiting VEGF signalling [70]. 
VEGFR-2 also plays a critical role in develop-
ment where it is expressed in embryonic
angioblasts, blood islands and angiogenic blood
vessels. VEGFR-2 null mouse embryos die at day
8.5–9.5 due to impaired development of both
endothelial and hematopoietic cells [68].
VEGF-C/VEGF-D signaling via VEGFR-3 is
crucial for the development of the embryonic vascu-
lar system and also for the maintenance of the lym-
phatic system. Cardiovascular failure and defective
remodeling of the primary vascular plexus occurs
after embryonic day 9.5 if VEGFR-3 is knocked out,
but vascular sprouting and network formation
occurs normally [71]. Neuropilin-1 is involved in
the developing neural system where it is expressed
by neurons and acts as a receptor for the class 3
semaphorins, which are involved in chemorepulsive
axonal guidance. It plays an essential role in the
directional guidance of nerve fibers as was deduced
from studies where NRP-1 null mutant mice dis-
played disorganized nerve pathways [72]. NRP-1
also plays a role in vasculogenesis during develop-
ment. Deletion of NRP-1 in the mouse embryo
results in defects in embryonic vascularisation and
cell death at day 12–13 [73]. Vascularisation of both
the central nervous system and peripheral nervous
system is also affected. Vascular regression is
observed and conversely, mice over-expressing
NRP-1 have excessive blood vessel formation [74].
NRP-2 knock-out is not embryonic lethal and
does not lead to an abnormal vascular phenotype
but double knockout of NRP-1 and NRP-2 leads to
a more severely abnormal vascular phenotype than
NRP-1 knockout alone, with mouse embryos dying
earlier at day 8.5. The abnormal vascular phenotype
in NRP1 and 2 knockout mice is similar to VEGFR-
2 deficient mice; blood islands are absent and
embryonic and yolk sac blood vessels are not
observed [73]. In the early developmental stages of
chick embryos, NRP-1 expression is restricted to
arteries whereas NRP-2 is primarily found on veins
of the developing vascular system, suggesting that
the neuropilins play a role in arterial/venous differ-
entiation [75]. NRP-2 has been implicated in lym-
phatic vessel formation and is co-expressed in lym-
phatic endothelial cells with VEGFR-3. NRP-2 null
mice display an absence or severe reduction in lym-
phatic vessels and capillaries in most tissues [76]. 
In summary, most of the VEGF receptors are
required to mediate normal embryonic angiogenesis
and development and coordinated controlled
expression of VEGF and its receptors is necessary
for normal growth and development. 
VEGF in normal adult physiology
In normal healthy adults VEGF signaling is largely
restricted to wound healing and the female repro-
ductive cycle.  
Wound healing
In wound healing, activated platelets release sever-
al cytokines including VEGF upon injury. VEGF
then attracts circulating neutrophils and monocytes
to the site of injury as part of the normal inflamma-
tory response. It is also released by monocytes, ker-
atinocytes and endothelial cells at the wound site
where it can act on capillaries [8]. VEGF also
increases permeability by affecting the endothelial
cell junction proteins, which could enhance the for-
mation of granulation tissue [77]. Receptor activa-
tion by VEGF then results in endothelial cell prolif-
eration and migration. In addition to stimulating
angiogenesis (sprouting of new vessels from pre-
existing vasculature), VEGF also plays a role in
vasculogenesis by recruiting endothelial progenitor
cells from the bone marrow for endothelial vessel
formation [78]. Finally, VEGF stimulates pericytes
to coat and stabilize the vasculature [8].
Reproductive cycle
VEGF plays an important role in the female repro-
ductive cycle as one of the primary angiogenic fac-
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tors regulating follicular and luteal vascular devel-
opment. It is present exclusively in the luteal con-
nective tissue and perivascular cells. In contrast to
pathological conditions, growth and angiogenesis
in the female reproductive cycle is highly regulated
and well coordinated [79]. VEGF expression is
highest in early luteal phase as the development of
new blood vessels is required for the corpus luteum,
declines after the mid-luteal phase when the vascu-
lature is established and is absent in the late corpus
luteum [80].
VEGF in non-malignant disease
Rheumatoid arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune dis-
ease, which affects the peripheral and synovial
joints. The synovium or lining becomes inflamed
and increases in mass. Cells within the synovium
invade and digest bone and cartilage, which leads
to the destruction of the joints. Angiogenesis is
recognized as playing an important role in the
maintenance and progression of RA. VEGF is
important in this disease by stimulating vascular
permeability and angiogenesis. Endothelial prolif-
eration is higher in synovial fluid in RA patients
compared to normal controls [81]. The increase in
the volume of synovial fluid induces a hypoxic
state by increasing the distance between prolifer-
ating cells and the nearest blood vessels. Increased
proliferation of the synovial cells increases the
demand for oxygen and nutrients thus increasing
the hypoxic environment which then stimulates
angiogenesis [82]. Serum VEGF levels are elevat-
ed in RA patients, the local hypoxia in the joints
probably contributing to these elevated levels
[83]. Radiography studies showed that the level of
serum VEGF correlates to the level of joint dam-
age [84]. Other pro-angiogenic factors are also
elevated in the synovial fluid of RA patients such
as Fibroblast Growth Factors (FGFs) and PDGF
[85]. Both VEGF121 and VEGF165 are expressed in
RA synovial fluid along with the VEGF receptors
Flt-1, KDR and NRP-1, all of which are elevated
compared to control patients [86].
The available evidence therefore suggests that
angiogenesis plays a crucial role in RA and tar-
geting VEGF may be of therapeutic benefit in this
condition. Studies in animal models of RA
showed that treatment with the soluble form of
Flt-1 (sFlt-1), which inhibits VEGF, significantly
reduced joint inflammation and reduced bone and
cartilage destruction [87].
Diabetes and ischemic retinopathies
Plasma VEGF is elevated in diabetic patients.
Elevated blood glucose exerts toxic effects on the
endothelium. It can induce a hyperglycemic pseu-
do-hypoxic state which in turn induces VEGF
production [88]. This has an effect on the
endothelium and plasma VEGF levels have been
shown to correlate to endothelial damage and dys-
function in diabetes [89]. More extensively stud-
ied is its role in diabetic retinopathy. Excessive
secretion of VEGF in the retina leads to ocular
neovascularisation, hemorrhages and it also pro-
motes vascular permeability, which results in
visual impairment/blindness. VEGF also con-
tributes to high ocular fluid levels found in
patients with this disease [8]. Elevated levels of
VEGF are found in the aqueous humor of glauco-
ma patients providing further evidence that VEGF
is an important factor in the pathology and intra-
occular neovascularisation in patients with ocular
disease [90]. 
Since VEGF is implicated in the pathological
development of retinal neovascularisation in
ischemic retinopathies, several strategies targeting
VEGF have been undertaken. An animal model of
ishemia-induced retinal neovascularisation was
treated with a chimeric protein of the VEGF recep-
tors VEGFR-1 and VEGFR-2. A single intravitre-
al injection of the chimeric protein into the eye
decreased retinal neovascularisation by up to
100% compared to those treated with a control
chimeric protein [91]. In another study using a
mouse model of ischemic retinopathy, treatment
by gavage with a drug (PTK787) that blocks phos-
phorylation by VEGF and PDGF receptors led to a
complete inhibition of retinal neovascularisation
[92]. Both of these results along with the elevated
levels of VEGF found in these pathologies indi-
cate that VEGF signaling plays an important role
in ischemic retinopathies making VEGF an ideal
target molecule in these diseases.
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Psoriasis
Psoriasis is a chronic skin condition caused by
inflammatory cell infiltrate and proliferation of
blood vessels. The reddened appearance of the skin
is caused by highly abnormal dermal blood vessels,
which are highly permeable and lead to edema [93].
Other characteristics include dermal thickening and
keratinocyte differentiation. The keratinocytes
over-express VEGF and its receptors, which leads
to neovascularisation [94]. In the psoriasis patient,
the skin is predisposed to the initiation of angio-
genesis if the correct stimuli are present. Excess
VEGF in the skin can induce a vascular inflamma-
tory response resulting in a more widespread tissue
inflammation [93].
In mice chronic transgenic delivery of VEGF to
the skin induces inflammation and all the character-
istics of psoriasis suggesting a causative role for
VEGF in this disease. Using a potent VEGF antag-
onist, the VEGF-Trap, reverses this phenotype [93].
Current treatment involves immunosuppressive and
anti-inflammatory drugs which have toxic effects
and are not always effective. Targeting VEGF may
be a novel approach to the treatment of psoriasis.
As a corollary, the treatment of other conditions
with VEGF stimulants could possibly result in
chronic skin inflammation as a side effect.
VEGF in malignant disease
Tumour angiogenesis
In order to grow beyond 2-3 mm3 tumours require
a vascular supply to provide nutrients and oxygen.
They achieve this by secreting angiogenic growth
factors such as VEGF in order to recruit a vascula-
ture from pre-existing blood vessels (angiogenesis).
VEGF is secreted by the tumour cells themselves
and infiltrating immune cells such as monocytes
[77]. VEGF binds to its receptors on the pre-exist-
ing endothelium, stimulating endothelial cell prolif-
eration and migration into the tumour resulting in
vascular sprouting. These sprouts ultimately form
new blood vessels within the tumour. VEGF also
plays a role in vasculogenesis by recruiting
endothelial progenitor cells from the bone marrow
for endothelial vessel formation [77]. The new vas-
culature also provides the tumour with a route by
which tumour cells can get into the blood circula-
tion and form distant metastases [95].
Elevated VEGF production by tumours is asso-
ciated with increased tumour vascularity, metasta-
sis, chemoresistance and poorer prognosis com-
pared to VEGF-negative tumours. Circulating
VEGF is elevated in breast, lung and gastrointesti-
nal cancers [96]. In post operative samples, breast
tumours over-expressing VEGF were associated
with early relapse compared to tumour samples
with low levels of VEGF [97]. VEGF expression
therefore can act as a prognostic factor where high
levels of VEGF in the circulation or tumour tissue
is negatively correlated to relapse free and overall
survival. It is unknown as of yet if this is solely due
to increased angiogenesis in a tumour or if VEGF
plays other roles in the progression of cancers.
Angiogenic switch
Angiogenesis depends on the balance of endoge-
nous pro-angiogenic stimulators and anti-angio-
genic inhibitors. Tumour growth creates an imbal-
ance by secreting pro-angiogenic factors to initiate
angiogenesis, the “angiogenic switch”[98]. It is not
yet understood why some tumours remain dormant
while others initiate angiogenesis and progress to a
malignant phenotype. Nyberg et al. (2005) [99] sug-
gested that the physiological balance between the
endogenous inhibitors and stimulators could predict
the individuals’ predisposition to the switch in
pathological conditions. If an individual has more
endogenous stimulators than inhibitors the balance
favors angiogenesis whereas if the individual has
more endogenous angiogenesis inhibitors it is more
difficult to switch to an angiogenic phenotype [99].
Autocrine effects of VEGF
It was originally thought that tumour cells secrete
VEGF in a paracrine manner in order to attract and
stimulate proliferation of endothelial cells. It has
since been shown that VEGF can also act in an
autocrine manner having a protective/survival
effect on a number of cell types including endothe-
lial cells, embryonic stem cells and hematopoietic
stem cells [100–102]. 
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We and others have also shown that VEGF can
act as an autocrine survival factor for the tumour
cells themselves [42, 103]. We showed that block-
ing VEGF with neutralising antibodies induced
apoptosis of two cell lines, the 4T1 murine mam-
mary adenocarcinoma and the human MDA-MB-
231 [104]. Similarly, blocking VEGF binding to
NRP-1 also induced apoptosis of these cells [43].
An elegant study by Dias et al. showed that inhibi-
tion of both the paracrine and autocrine VEGF sig-
naling pathways was required to achieve complete
remission of human leukemia xenografts [105].
Tumour cells have been shown to secrete elevat-
ed levels of VEGF under stressed conditions such
as serum starvation (in vitro), hypoxia, radiation
and chemotherapy [106–109]. Inadvertently, stress-
es such as radiotherapy or chemotherapy can there-
fore contribute to enhanced survival of tumour cells
due to elevated VEGF and render them less sensi-
tive to conventional chemotherapy and radiothera-
py treatments [110, 111]. This chemoprotectant
effect requires VEGF signaling via the PI3-Kinase
pathway. More recently a member of the inhibitor
of apoptosis family, survivin, has been implicated
in VEGF-mediated chemo-resistance.  Survivin lev-
els increased 10–20 fold in endothelial cells stimu-
lated with VEGF.  PI3-Kinase inhibition down reg-
ulated VEGF-mediated survivin expression.
Inhibition of survivin also decreased VEGF mediat-
ed chemoresistance of endothelial cells. VEGF sig-
naling through survivin preserves cellular integrity
in the presence of chemotherapy by stabilizing the
microtubule network and maintaining their
cytoskeletal integrity [112]. Tumour cell expression
of survivin has also been shown and a correlation to
its apoptotic function is linked to its ability to inhib-
it caspases, which could also contribute to chemore-
sistance [113].
Targeting VEGF should block both the pro-
angiogenic (paracrine) and pro-survival (autocrine)
effects of VEGF including survivin inhibition, and
thereby sensitise tumour cells to conventional ther-
apies both by reducing angiogenesis and blocking
an autocrine survival effect [101].
Tumour lymphatics
The lymphatics in a tumour also play a role in its
growth and metastases. Generally the lymphatics
within the tumour are compressed and non func-
tional, but they are enlarged at the periphery due to
excess VEGF C expression. These lymphatics col-
lect interstitial fluid and metastatic tumour cells
resulting in lymphatic metastases [19]. 
VEGF and hypoxia
All cell types, including tumour cells, require
oxygen for energy production and tissue function.
Lack of an adequate blood supply and increasing
distances from existing blood vessels means
tumour cells are starved of oxygen. This leads to
areas of hypoxia or even anoxia in the tumour. In
tumours, hypoxia can lead to malignant progres-
sion by inducing adaptive changes in tumour cells
to enable survival in this harsh environment.
These include changes in gene expression, inacti-
vation of tumour suppressor genes, activation of
oncogenes, genomic instability and clonal selec-
tion. The harsh environment exerts a strong selec-
tive pressure on tumour cells selecting for the
most malignant in a “survival of the fittest” mech-
anism. The cells adapted to hypoxia proliferate
and survive better than the non-adaptive ones and
become the predominant population in the tumour
leading to a more aggressive phenotype. Down
regulation of adhesion molecules in response to
hypoxia increases tumour cell detachment and
thus metastasis [114].
Other problems associated with tumour
hypoxia are the direct and indirect effects it has
on chemo-resistance. Some chemotherapy drugs
such as alkylating agents are less effective in
hypoxic conditions. In response to hypoxia, the
cells cycle slows down or arrests in G1. Since
some chemotherapies act at the S1 phase of the
cell cycle inhibiting DNA synthesis they are
thus less effective in a hypoxic environment
[115]. Hypoxia selects for mutations in the p53
tumour suppressor gene. Cells with mutations in
p53 are resistant to DNA damage induced apop-
tosis and are more likely to be chemoresistant
than cells with wild type p53. p53 mutation
results in decreased hypoxia mediated apoptosis
and increased VEGF production [116].
Induction of the multi-drug resistant protein
(MDR) gene expression has also been observed
under hypoxia [117].
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In radiotherapy hypoxia poses a problem also
as radiotherapy acts on rapidly proliferating
cells and depends on the presence of oxygen to
increase the reactive oxygen species. Radio-sen-
sitivity decreases at low tumour oxygen concen-
trations. Oxygen actually enhances radiation as
it increases DNA damage by formation of oxy-
gen-derived free hydroxyl radicals, which
occurs directly after radiotherapy. In fact the
dose of radiation required for tumour cell apop-
tosis is 2–3 times higher in hypoxic conditions
than normoxic [118].
In the clinical setting tumour hypoxia corre-
lates to shorter survival compared to patients
with hypoxia free tumours. A correlation
between tumour hypoxia and malignant progres-
sion in uterine cervical cancer has been estab-
lished and it can act as a marker of poor outcome
and overall survival in soft tissue and head and
neck cancers [119].
In response to hypoxia, tumours secrete angio-
genic growth factors to stimulate vessel growth
and oxygen delivery. This is mediated by a
hypoxia inducible factor (HIF-1), which modu-
lates the expression of a number of hypoxia
inducible genes and angiogenic factors such as
VEGF. HIF-1 consists of 2 subunits HIF-1α and
HIF-1β. HIF-1α is a cytoplasmic protein and is
responsive to oxygen levels whereas HIF-1β is a
nuclear protein expressed independently of oxy-
gen tension.  In normoxia, HIF1α is rapidly
degraded.  In response to hypoxia, HIF-1α is sta-
bilized and translocates to the nucleus, het-
erodimerises with HIF-1β forming an active HIF-
1 protein. This protein binds to specific hypoxia
response elements (HREs) within the promoter of
hypoxia-inducible genes and activates transcrip-
tion [120]. Another protein involved in hypoxia-
induced VEGF expression is HuR. This protein
binds and stabilizes the VEGF mRNA message
and promotes transfer to the cytoplasm [121].
VEGF is also up regulated in response to
hypoxia in physiological situations including
wound healing, ovulation and atherosclerosis.
Up-regulation is also observed in patients with
diabetic retinopathy.  The presence of hypoxia in
tumours reflects a poorer prognosis with
increased treatment failure and decreased overall
survival. Overcoming hypoxia in the tumour envi-
ronment should lead to a better outcome.
Targeting VEGF as cancer therapy 
Since VEGF plays such an important role in tumour
progression and metastasis it is an attractive target
in the treatment of cancer. In tumours, the vascula-
ture is haphazard, disorganized and comprises of
leaky blood vessels and excessive branching. It is
structurally and functionally abnormal. This leads
to poor drug delivery and hypoxic areas within the
tumour. Interstitial fluid pressure is elevated in a
tumour due to the hyperpermeable vessels, which
also impairs drug penetration [122]. Targeting the
tumour vasculature deprives it of the nutrients and
oxygen necessary for growth. This approach should
also inhibit metastasis. Unfortunately there are no
tumour specific anti-angiogenic compounds and
thus, to date, treatment with anti-angiogenics alone
is unable to cause tumour regression. However,
these agents are likely to prove useful in disease
stabilization. Increasing the dose of these com-
pounds can have an adverse effect on the normal
vasculature thereby limiting its use. In combination
with conventional chemotherapy, anti-angiogenic
strategies have a synergistic effect. 
Many anti-angiogenic strategies have been
undertaken to date including anti-VEGF antibod-
ies such as bevacizumab (Avastin, Genentech Inc),
soluble VEGF receptor analogues such as the
VEGF TRAP, small molecule VEGF inhibitors
such as SU5416, SU11248, PTK787/ZK222584
and ribozymes such as angiozyme [123]. Targeting
the more novel VEGF receptor NRP-1 with pep-
tides has also shown some promising pre-clinical
data [43, 124].
Normalisation theory
Although reducing tumour vasculature inhibits
tumour growth and metastasis, it might also be
expected that a decrease in tumour vasculature would
decrease the efficacy of drug delivery. This however
is not the case as anti-angiogenic therapy actually
increases the efficacy of chemotherapy or radiothera-
py [106, 125]. To explain this paradox, Rakesh Jain
suggested that treating the tumour with an anti-angio-
genic compound attacked the less stable, leaky blood
vessels first. This in effect creates a more normal sta-
ble vasculature in the tumour environment, which can
now deliver oxygen and nutrients more efficiently
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[126]. One would expect however that the increase in
nutrients and oxygen delivery to the tumour would
increase tumour growth. Cytotoxic drug therapy dur-
ing this normalization period is more efficiently
delivered throughout the tumour, as chemotherapy
delivery is usually impaired due to the lack of an effi-
cient delivery system (vasculature). The increase in
oxygen may increase proliferation of cells but
chemotherapy and radiotherapy actually work better
on rapidly proliferating cells [127]. In addition, as
VEGF production is increased in response to cytotox-
ic therapy or radiotherapy, anti-angiogenic therapies
that block VEGF will also block the autocrine pro-
survival activity of VEGF rendering the cells more
sensitive to chemotherapy and radiotherapy [103].
The more efficient oxygen delivery with the nor-
malized vasculature decreases the hypoxic areas of
the tumour. Hypoxia as discussed above can actual-
ly enhance tumour progression by increasing genet-
ic instability and selecting for tumour cells with a
more resistant phenotype capable of surviving in
this environment. Hypoxic cells also have an
increased metestatic potential [115]. Decreasing the
hypoxic areas with this normalisation process
should render the cells more sensitive to the
chemotherapy that is now delivered more efficient-
ly. The anti-angiogenic drugs may also target the
tumour cells themselves most notably those express-
ing the VEGF receptors and where VEGF acts as a
survival factor. The normalised vasculature is less
likely to be permeable to shedded tumour cells,
which form distant metastases [126, 127].
This combination therapy should enhance tumour
treatment as it increases chemo and radio delivery,
decreases hypoxia and sensitises tumour cells by
overcoming the production of survival factors. It
should also decrease the number of metastases. Doses
and treatment schedules need to be carefully selected
to achieve this normalization window where it is opti-
mal to treat with chemotherapy. In support of the nor-
malization hypothesis, a number of clinical trials have
shown synergistic effects of anti-angiogenics in com-
bination with chemotherapy [128, 129].
Metronomic therapy: chemotherapy as
anti-angiogenic therapy
The initial approach to the treatment of tumours
was to target the tumour cells with the maximum
tolerated doses (MTD) of a cytotoxic agent. This
unfortunately leads to many undesirable side
effects and damage to normal cells such as bone
marrow progenitors, hematopoietic stem cells and
hair follicles.  It can also lead to myelosuppres-
sion. To overcome these toxic effects a treatment
free period in the chemotherapy schedule is
required to allow normal cells to recover.
Unfortunately during this period the tumour cells
and tumour associated endothelial cells can also
recover and the tumour cells may become resis-
tant to further treatment [130].
A new schedule was proposed by Kerbel et al.
(2004) [130] to decrease the dose of chemothera-
py but to increase the frequency of administration.
By doing this the intervals between doses can be
decreased as the toxic side effects are reduced.
This has been termed “metronomic dosing” [130].
The shorter interval time did not allow for the
endothelial and tumour cells to recover and
tumour cells were less likely to become resistant
to the chemotherapy. By using this regimen, an
increase in apoptosis of endothelial and tumour
cells was observed and overall tumour growth was
suppressed more efficiently than by using the con-
ventional MTD dosing and schedules [131]. The
reasons this therapy is more efficacious are not
fully understood but there are a number of
hypotheses put forward.
One of the main hypotheses is that the metro-
nomic dosing acts as an anti-angiogenic therapy.
Since the endothelial cells proliferate at a lower
rate than the tumour cells, they are less affected
by the chemotherapy drugs, which act more effi-
ciently on rapidly dividing cells. The recovery of
the endothelial cells during the drug free periods
can support the growth and emergence of
chemoresistant tumour cells. Using metronomic
treatment targets these endothelial cells in the
tumour bed as it is given in a continuous mode.
This results in tumour cell apoptosis via an anti-
angiogenic mechanism as opposed to a direct
cytotoxic effect and is independent of the resis-
tance to chemotherapy. This has also been termed
the anti-angiogenic schedule [130].
Along with recruiting a blood supply from pre-
existing blood vessels (angiogenesis) tumours can
acquire a vasculature by recruiting progenitor
cells from the bone marrow for the generation of
blood vessels (vasculogenesis). This involves the
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mobilization of viable circulating endothelial pro-
genitors (CEPs) to the tumour. The induction of
myelosuppression by the chemotherapy causes a
response by the host, which is seen by the marked
increase and mobilization of hematopoietic pro-
genitors from the bone marrow to the peripheral
blood stream. With treatment using the conven-
tional MTD schedule a robust CEP mobilization
is observed at the end of the drug cycle, during
the drug free interval. The influx of CEPs to a
tumour replaces damaged endothelial cells there-
by promoting tumour growth. An increase in
CEPs parallels tumour growth and a correlation
between circulating endothelial cells (CECs) and
VEGF in tumour bearing mice has been observed
[132]. In contrast to the MTD schedule, CEPs
were not mobilized in response to the metronom-
ic schedule and CEP viability was decreased. An
increase in CEP apoptosis was also observed. The
anti-vasculogenesis effects of metronomic dosing
support the hypothesis that it directly targets the
endothelial cells and thereby indirectly targets the
tumour cells [133].
A secondary effect observed by Boci et al.
was an increase in the levels of endogenous
angiogenesis inhibitor thrombospondin-1 (TSP-
1) in the plasma of mice treated with metronom-
ic chemotherapy [134]. TSP-1 is highly specific
for endothelial cells where it inhibits prolifera-
tion and induces apoptosis. Since metronomic
therapy induces TSP-1 it may be the reason why
endothelial cells are specifically targeted. TSP-1
like other endogenous inhibitors may also
decrease the CEPs which would also support the
previous theory [134].
This novel approach to chemotherapy treat-
ment suggests that anti-angiogenic scheduling of
chemotherapy may improve outcome and reduce
side effects seen with the conventional MTD
chemotherapy regimes. Combining chemotherapy
with a specific anti-angiogenic compound such as
a neutralising antibody of VEGFR-2 (DC101)
was shown to completely eradicate an orthotopi-
cally transplanted multi drug resistant human
breast tumour (MDA-MB 231 and MDA-MB 435
variants) in SCID mice [135]. This metronomic
therapy is actually an indirect (by increasing TSP-
1 levels and effect on CEPs) as well as direct
(cytotoxic to endothelial cells) attack on the
tumour vasculature and provides a novel
approach for using chemotherapy as an anti
angiogenic as opposed to simply a cytotoxic agent
in the treatment of tumours.
Conclusions
VEGF plays important roles in angiogenesis and
cell survival pathways. In healthy adults its role is
mainly limited to angiogenesis during wound heal-
ing and the menstrual cycle. It also plays a crucial
role during embryogenesis. VEGF plays important
roles in a number of human pathologies especially
in cancer. Tumours secrete VEGF to stimulate new
vessel formation, particularly in response to
hypoxia. These new vessels provide oxygen and
nutrients to the tumour but also allow tumour cells
access to the circulation facilitating metastasis. In
addition to stimulating angiogenesis, it appears that
VEGF may also have autocrine functions acting as
a survival factor for tumour cells protecting them
from stresses such as hypoxia, chemotherapy and
radiotherapy.  Angiogenesis and VEGF in particu-
lar, are attractive targets for anti-cancer strategies
and blocking VEGF has been shown to both block
angiogenesis and improve the efficacy of
chemotherapy and radiotherapy.
References
1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA,
Harvey VS, Dvorak HF. Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites
fluid. Science 1983; 219: 983–5.
2. Ferrara N, Henzel WJ. Pituitary follicular cells secrete
a novel heparin-binding growth factor specific for vascu-
lar endothelial cells. Biochem Biophys Res Commun.
1989; 161: 851–8.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV,
Ferrara N. Vascular endothelial growth factor is a secret-
ed angiogenic mitogen. Science 1989; 246: 1306-1309,
4. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T,
Feder J, Connolly DT. Vascular permeability factor, an
endothelial cell mitogen related to PDGF. Science 1989;
246: 1309–12.
5. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F,
Familletti PC, Pan YC, Olander JV, Connolly DT,
Stern D. Vascular permeability factor: a tumor-derived
polypeptide that induces endothelial cell and monocyte
789
J. Cell. Mol. Med. Vol 9, No 4, 2005
procoagulant activity, and promotes monocyte migration.
J Exp Med. 1990; 172: 1535–45.
6. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z.
Vascular endothelial growth factor (VEGF) and its recep-
tors. FASEB J. 1999; 13: 9–22.
7. Tischer E, Mitchell R, Hartman T, Silva M,
Gospodarowicz D, Fiddes JC, Abraham JA. The
human gene for vascular endothelial growth factor.
Multiple protein forms are encoded through alternative
exon splicing. J Biol Chem. 1991; 266: 11947–54.
8. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van
Oosterom AT, De Bruijn EA. Vascular endothelial
growth factor and angiogenesis. Pharmacol Rev. 2004;
56: 549–80.
9. Park JE, Keller GA, Ferrara N. The vascular endothe-
lial growth factor (VEGF) isoforms: differential deposi-
tion into the subepithelial extracellular matrix and bioac-
tivity of extracellular matrix-bound VEGF. Mol Biol Cell.
1993; 4: 1317–26.
10. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L,
Pritchard-Jones RO, Cui TG, Sugiono M, Waine E,
Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles,
CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ,
Bates DO. VEGF165b, an inhibitory vascular endothelial
growth factor splice variant: mechanism of action, in vivo
effect on angiogenesis and endogenous protein expres-
sion. Cancer Res. 2004; 64: 7822–35.
11. Olofsson B, Pajusola K, Kaipainen A, von Euler G,
Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo
K, Eriksson U. Vascular endothelial growth factor B, a
novel growth factor for endothelial cells. Proc Natl Acad
Sci USA. 1996; 93: 2576–81.
12. Gollmer JC, Ladoux A, Gioanni J, Paquis P, Dubreuil
A, Chatel M, Frelin C. Expression of vascular endothe-
lial growth factor-b in human astrocytoma. Neurooncol.
2000; 2: 80–6,
13. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K-
i, Hamakawa H. Expression of vascular endothelial
growth factor A, B, C, and D in oral squamous cell carci-
noma. Oral Oncology 2004; 40: 13.
14. Kawakami M, Furuhata T, Kimura Y, Yamaguchi K,
Hata F, Sasaki K, Hirata K. Expression analysis of vas-
cular endothelial growth factors and their relationships to
lymph node metastasis in human colorectal cancer. J Exp
Clin Cancer Res. 2003; 22: 229–37.
15. Joukov V, Pajusola K, Kaipainen A, Chilov D,
Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo
K. A novel vascular endothelial growth factor, VEGF-C,
is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2)
receptor tyrosine kinases. EMBO J. 1996; 15: 1751.
16. Lee J, Gray A, Yuan J, Luoh SM. Avraham H, Wood
WI. Vascular endothelial growth factor-related protein: a
ligand and specific activator of the tyrosine kinase recep-
tor Flt4. Proc Natl Acad Sci USA. 1996; 93: 1988–92.
17. Makinen T, Veikkola T, Mustjoki S, Karpanen T,
Catimel B, Nice EC, Wise L, Mercer A, Kowalski H,
Kerjaschki D, Stacker SA, Achen MG, Alitalo K.
Isolated lymphatic endothelial cells transduce growth,
survival and migratory signals via the VEGF-C/D recep-
tor VEGFR-3. EMBO J. 2001; 20: 4762–73.
18. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali
A, Wilks AF, Alitalo K, Stacker SA. Vascular
endothelial growth factor D (VEGF-D) is a ligand for
the tyrosine kinases VEGF receptor 2 (Flk1) and
VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA.
1998; 95: 548–53.
19. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M,
Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo
K. Hyperplasia of lymphatic vessels in VEGF-C trans-
genic mice. Science 1997; 276: 1423–5.
20 Meyer M, Clauss M, Lepple-Wienhues A,
Waltenberger J, Augustin HG, Ziche M, Lanz C,
Buttner M, Rziha, HJ, Dehio C. A novel vascular
endothelial growth factor encoded by Orf virus, VEGF-E,
mediates angiogenesis via signalling through VEGFR-2
(KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinas-
es. EMBO J. 1999; 18: 363–74.
21. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A,
Matsushime H, Sato M. Nucleotide sequence and
expression of a novel human receptor-type tyrosine
kinase gene (flt) closely related to the fms family.
Oncogene 1990; 5: 519–24.
22. Terman BI, Carrion ME, Kovacs E, Rasmussen BA,
Eddy RL, Shows TB. Identification of a new endothelial
cell growth factor receptor tyrosine kinase. Oncogene
1991; 6: 1677–83.
23. Soker S, Takashima S, Miao HQ, Neufeld G,
Klagsbrun M. Neuropilin-1 is expressed by endothelial
and tumor cells as an isoform-specific receptor for vascu-
lar endothelial growth factor. Cell 1998; 92: 735–45.
24. Park JE, Chen HH, Winer J, Houck KA, Ferrara N.
Placenta growth factor. Potentiation of vascular endothe-
lial growth factor bioactivity, in vitro and in vivo, and
high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol
Chem. 1994; 269: 25646–54.
25. Tanaka K, Yamaguchi S, Sawano A, Shibuya M.
Characterization of the extracellular domain in vascular
endothelial growth factor receptor-1 (Flt-1 tyrosine
kinase). Jpn J Cancer Res. 1997; 88: 867–76.
26. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani,
A, Marme D. Migration of human monocytes in response
to vascular endothelial growth factor (VEGF) is mediated
via the VEGF receptor flt-1. Blood 1996; 87: 3336–43.
27. Zachary I, Gliki G. Signaling transduction mechanisms
mediating biological actions of the vascular endothelial
growth factor family. Cardiovasc Res. 2001; 49: 568–81.
28. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour
O, Shibuya M, Wijelath ES. Expression of vascular
endothelial growth factor receptors in smooth muscle
cells. J Cell Physiol. 2001; 188: 359–68.
29. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W,
Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ,
Ellis LM. Expression and function of vascular endothe-
lial growth factor receptor-1 on human colorectal cancer
cells. Oncogene 2005; 24: 2647–53.
30. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF,
Somcio R, Liu W, Evans DB, Wu Y, Hicklin DJ, Ellis
LM. Vascular endothelial growth factor receptor-1 pro-
motes migration and invasion in pancreatic carcinoma
cell lines. Cancer 2005; 104: 427–38.
790
31. Gille H, Kowalski J, Li B, LeCouter J, Moffat B,
Zioncheck TF, Pelletier N, Ferrara N. Analysis of bio-
logical effects and signaling properties of Flt-1 (VEGFR-
1) and KDR (VEGFR-2). A reassessment using novel
receptor-specific vascular endothelial growth factor
mutants. J Biol Chem. 2001; 276: 3222–30.
32. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham
H. Role of Vascular Endothelial Growth Factor in the
stimulation of cellular invasion and signaling of breast
cancer cells. Cell Growth Differ. 2001; 12: 129–35.
33. Meister B, Grunebach F, Bautz F, Brugger W, Fink
FM, Kanz L, Mohle R. Expression of vascular endothe-
lial growth factor (VEGF) and its receptors in human neu-
roblastoma. Eur J Cancer. 1999; 35: 445–9.
34. Tian X, Song S, Wu J, Meng L, Dong Z, Shou C.
Vascular endothelial growth factor: acting as an autocrine
growth factor for human gastric adenocarcinoma cell
MGC803. Biochem Biophys Res Commun. 2001; 286:
505–12.
35. Galland F, Karamysheva A, Pebusque MJ, Borg JP,
Rottapel R, Dubreuil P, Rosnet O, Birnbaum D. The
FLT4 gene encodes a transmembrane tyrosine kinase
related to the vascular endothelial growth factor receptor.
Oncogene 1993; 8: 1233–40.
36. Kaipainen A, Korhonen J, Mustonen T, van
Hinsbergh VW, Fang GH, Dumont D, Breitman M,
Alitalo K. Expression of the fms-like tyrosine kinase 4
gene becomes restricted to lymphatic endothelium during
development. Proc Natl Acad Sci USA. 1995; 92:
3566–70. 
37. Fujisawa H, Kitsukawa T. Receptors for collapsin-
semaphorins. Curr Opin Neurobiol. 1998; 8: 587–92.
38. Soker S, Fidder H, Neufeld G, Klagsbrun M.
Characterization of novel vascular endothelial growth
factor (VEGF) receptors on tumor cells that bind
VEGF165 via its exon 7-encoded domain. J Biol Chem.
1996; 271: 5761–7.
39. Fuh G, Garcia KC, de Vos AM. The interaction of neu-
ropilin-1 with vascular endothelial growth factor and its
receptor flt-1. J Biol Chem. 2000; 275: 26690–5.
40. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular
endothelial growth factor receptor-2 and neuropilin-1
form a receptor complex that is responsible for the differ-
ential signaling potency of VEGF(165) and VEGF(121).
J Biol Chem. 2001; 276: 25520–31.
41. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun
M. VEGF165 mediates formation of complexes contain-
ing VEGFR-2 and neuropilin-1 that enhance VEGF165-
receptor binding. J Cell Biochem. 2002; 85: 357–68.
42. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw
LM, Robinson G, Mercurio AM. Vascular endothelial
growth factor is an autocrine survival factor for neu-
ropilin-expressing breast carcinoma cells. Cancer Res.
2001; 61: 5736–40.
43. Barr MP, Byrne AM, Duffy AM, Condron CM,
Devocelle M, Harriott P, Bouchier-Hayes DJ, Harmey
JH. A peptide corresponding to the neuropilin-1-binding
site on VEGF(165) induces apoptosis of neuropilin-1-
expressing breast tumour cells. Br J Cancer 2005; 92:
328–33.
44. Ding H, Wu X, Roncari L, Lau N, Shannon P, Nagy A,
Guha A. Expression and regulation of neuropilin-1 in
human astrocytomas. Int J Cancer 2000; 88: 584–92.
45. Fakhari M, Pullirsch D, Abraham D, Paya K,
Hofbauer R, Holzfeind P, Hofmann M, Aharinejad S.
Selective upregulation of vascular endothelial growth fac-
tor receptors neuropilin-1 and -2 in human neuroblas-
toma. Cancer 2002; 94: 258–63.
46. Lantuejoul S, Constantin B, Drabkin H, Brambilla C,
Roche J, Brambilla E. Expression of VEGF, semaphorin
SEMA3F, and their common receptors neuropilins NP1
and NP2 in preinvasive bronchial lesions, lung tumours,
and cell lines. J Pathol. 2003; 200: 336–47.
47. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N,
Bruns CJ, Bucana CD, Evans DB, Ellis LM.
Expression and regulation of the novel vascular endothe-
lial growth factor receptor neuropilin-1 by epidermal
growth factor in human pancreatic carcinoma. Cancer
2003; 98: 720–9.
48. Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda
A, Fan F, Stoeltzing O, Parikh AA, Jung YD, Bucana
CD, Mansfield PF, Hicklin DJ, Ellis LM. Induction of
neuropilin-1 and vascular endothelial growth factor by
epidermal growth factor in human gastric cancer cells. Br
J Cancer 2003; 88: 796–802.
49. Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O,
Reinmuth N, Bielenberg D, Bucana CD, Klagsbrun M,
Ellis LM. Neuropilin-1 in human colon cancer: expres-
sion, regulation, and role in induction of angiogenesis.
Am J Pathol. 2004; 164: 2139–51.
50. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G.
Neuropilin-2 is a receptor for the vascular endothelial
growth factor (VEGF) forms VEGF-145 and VEGF-165.
J Biol Chem. 2000; 275: 18040–5.
51. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G.
Vascular endothelial growth factor receptor-1 and neu-
ropilin-2 form complexes. J Biol Chem. 2001; 276:
18688–94.
52. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood
JD, Granger HJ, Ledda F, Ziche M. Nitric oxide is an
upstream signal of vascular endothelial growth factor-
induced extracellular signal-regulated kinase1/2 activa-
tion in postcapillary endothelium. J Biol Chem. 1998;
273: 4220–6.
53. Pedram A, Razandi M, Levin ER. Extracellular signal-
regulated protein kinase/Jun kinase cross-talk underlies
vascular endothelial cell growth factor-induced endothe-
lial cell proliferation. J Biol Chem. 1998; 273: 26722–8.
54. Kroll J, Waltenberger J. The vascular endothelial
growth factor receptor KDR activates multiple signal
transduction pathways in porcine aortic endothelial cells.
J Biol Chem. 1997; 272: 32521–7.
55. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt
BA, Dixit V, Ferrara N. Vascular endothelial growth fac-
tor regulates endothelial cell survival through the phos-
phatidylinositol 3’-kinase/Akt signal transduction path-
way. Requirement for Flk-1/KDR activation. J Biol
Chem. 1998; 273: 30336–43.
56. Carmeliet P, Lampugnani MG, Moons L, Breviario
F, Compernolle V, Bono F, Balconi G, Spagnuolo R,
791
J. Cell. Mol. Med. Vol 9, No 4, 2005
Oostuyse B, Dewerchin M, Zanetti A, Angellilo A,
Mattot V, Nuyens D, Lutgens E, Clotman F, de
Ruiter, MC, Gittenberger-de Groot A, Poelmann
R, Lupu F, Herbert JM, Collen D, Dejana E.
Targeted deficiency or cytosolic truncation of the VE-
cadherin gene in mice impairs VEGF-mediated
endothelial survival and angiogenesis, Cell 1999; 98:
147–57.
57. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane, W,
Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ,
Witte L, Moore MA, Rafii S. Autocrine stimulation of
VEGFR-2 activates human leukemic cell growth and
migration. J Clin Invest. 2000; 106: 511–21.
58. Grosskreutz CL, Anand-Apte B, Duplaa C, Quinn TP,
Terman BI, Zetter B, D’Amore PA. Vascular endothe-
lial growth factor-induced migration of vascular smooth
muscle cells in vitro. Microvasc Res. 1999; 58: 128–36.
59. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani
A, Marme D. Migration of human monocytes in response
to vascular endothelial growth factor (VEGF) is mediated
via the VEGF receptor flt-1. Blood 1996; 87: 3336–43.
60. Qi JH, Claesson-Welsh L. VEGF-induced activation of
phosphoinositide 3-kinase is dependent on focal adhesion
kinase. Exp Cell Res. 2001; 263: 173–82.
61. Rousseau S, Houle F, Landry J, Huot J. p38 MAP
kinase activation by vascular endothelial growth factor
mediates actin reorganization and cell migration in
human endothelial cells. Oncogene 1997; 15: 2169–77.
62. Bernatchez PN, Soker S, Sirois MG. Vascular endothe-
lial growth factor effect on endothelial cell proliferation,
migration, and platelet-activating factor synthesis is Flk-
1-dependent. J Biol Chem. 1999; 274: 31047–54.
63. Takahashi T, Fournier A, Nakamura F, Wang LH,
Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM.
Plexin-neuropilin-1 complexes form functional
semaphorin-3A receptors. Cell 1999; 99: 59–69.
64. Bachelder RE, Lipscomb EA, Lin X, Wendt MA,
Chadborn NH, Eickholt BJ, Mercurio AM. Competing
autocrine pathways involving alternative neuropilin-1 lig-
ands regulate chemotaxis of carcinoma cells. Cancer Res.
2003; 63: 5230–3.
65. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino
JG, Evans DB, Ellis LM, Gallick GE. Neuropilin-1 sup-
presses tumorigenic properties in a human pancreatic ade-
nocarcinoma cell line lacking neuropilin-1 coreceptors.
Cancer Res. 2005; 65: 3664–70.
66. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF,
Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun
M, Gallick GE, Ellis LM. Overexpression of neuropilin-
1 promotes constitutive MAPK signalling and chemore-
sistance in pancreatic cancer cells. Br J Cancer 2005; 93:
223–41.
67. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L,
O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW.
Heterozygous embryonic lethality induced by targeted
inactivation of the VEGF gene. Nature 1996; 380:
439–42.
68. Tammela T, Enholm B, Alitalo K, Paavonen K. The
biology of vascular endothelial growth factors.
Cardiovasc Res. 2005; 65: 550–63.
69. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo
K. Regulation of angiogenesis via vascular endothelial
growth factor receptors. Cancer Res. 2000; 60: 203–12.
70. Kendall RL, Wang G, Thomas KA. Identification of a
natural soluble form of the vascular endothelial growth
factor receptor, FLT-1, and its heterodimerization with
KDR. Biochem Biophys Res Commun. 1996; 226: 324–8. 
71. Dumont DJ, Jussila L, Taipale J, Lymboussaki A,
Mustonen T, Pajusola K, Breitman M, Alitalo K.
Cardiovascular failure in mouse embryos deficient in
VEGF receptor-3. Science 1998; 282: 946–9.
72. Kitsukawa T, Shimizu M, Sanbo M, Hirata T,
Taniguchi M, Bekku Y, Yagi T, Fujisawa H.
Neuropilin-semaphorin III/D-mediated chemorepulsive
signals play a crucial role in peripheral nerve projection
in mice. Neuron 1997; 19: 995–1005.
73. Takashima S, Kitakaze M, Asakura M, Asanuma H,
Sanada S, Tashiro F, Niwa H, Miyazaki Ji J, Hirota S,
Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M,
Hori M. Targeting of both mouse neuropilin-1 and neu-
ropilin-2 genes severely impairs developmental yolk sac
and embryonic angiogenesis. Proc Natl Acad Sci USA.
2002; 99: 3657–62.
74. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H.
Developmentally regulated expression of a cell surface
protein, neuropilin, in the mouse nervous system. J
Neurobiol. 1996; 29: 1-17.
75. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld
G. Differential expression of neuropilin-1 and neuropilin-
2 in arteries and veins. Mech Dev. 2001; 109: 115–9.
76. Yuan L, Moyon D, Pardanaud L, Breant C,
Karkkainen MJ, Alitalo K, Eichmann A. Abnormal
lymphatic vessel development in neuropilin 2 mutant
mice. Development 2002; 129: 4797–806.
77. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de
Water L, Senger DR. Vascular permeability factor/vas-
cular endothelial growth factor: an important mediator of
angiogenesis in malignancy and inflammation. Int Arch
Allergy Immunol. 1995; 107: 233–5. 
78. Takahashi T, Ueno H, Shibuya M. VEGF activates pro-
tein kinase C-dependent, but Ras-independent Raf-MEK-
MAP kinase pathway for DNA synthesis in primary
endothelial cells. Oncogene 1999; 18: 2221–30.
79. Reynolds LP, Redmer DA. Expression of the angiogenic
factors, basic fibroblast growth factor and vascular
endothelial growth factor, in the ovary. J Anim Sci. 1998;
76: 1671–81.
80. Otani N, Minami S, Yamoto M, Shikone T, Otani H,
Nishiyama R, Otani T, Nakano R. The vascular
endothelial growth factor/fms-like tyrosine kinase sys-
tem in human ovary during the menstrual cycle and
early pregnancy. J Clin Endocrinol Metab. 1999; 84:
3845–51.
81. Walsh DA, Wade M, Mapp PI, Blake DR. Focally reg-
ulated endothelial proliferation and cell death in human
synovium. Am J Pathol. 1998; 152: 691–702.
82. Etherington PJ, Winlove P, Taylor P, Paleolog E
Miotla JM. VEGF release is associated with reduced
oxygen tensions in experimental inflammatory arthritis.
Clin Exp Rheumatol. 2002; 20: 799–805.
792
83. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH,
Cho CS, Kim HY. Vascular endothelial growth factor
levels in the serum and synovial fluid of patients with
rheumatoid arthritis. Clin Exp Rheumatol. 2001; 19:
321–4.
84. Paleolog E. Angiogenesis in rheumatoid arthritis.
Arthritis Res. 2002; 4: S81–90.
85. Koch AE. The role of angiogenesis in rheumatoid arthri-
tis: recent developments. Ann Rheum Dis. 2000; 59:
i65–71.
86. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E.
Expression of vascular endothelial growth factor isoforms
and their receptors Flt-1, KDR, and neuropilin-1 in syn-
ovial tissues of rheumatoid arthritis. J Pathol. 2000; 191:
426–33.
87. Miotla J, Maciewicz R, Kendrew J, Feldmann M,
Paleolog E. Treatment with soluble VEGF receptor
reduces disease severity in murine collagen-induced
arthritis. Lab Invest. 2000; 80: 1195–205.
88. Tilton RG, Kawamura T, Chang K C, Ido Y, Bjercke,
RJ, Stephan CC, Brock TA, Williamson JR. Vascular
dysfunction induced by elevated glucose levels in rats is
mediated by vascular endothelial growth factor. J Clin
Invest. 1997; 99: 2192–202.
89. Lim HS, Blann AD, Chong AY, Freestone B, Lip GYH.
Plasma vascular endothelial growth factor, angiopoietin-
1, and angiopoietin-2 in diabetes: implications for cardio-
vascular risk and effects of multifactorial intervention.
Diabetes Care 2004; 27: 2918–24.
90. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis
AP. Increased level of vascular endothelial growth factor
in aqueous humor of patients with neovascular glaucoma.
Ophthalmology 1998; 105: 232–7.
91. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H,
Riddle L, Ferrara N, King GL, Smith LE. Suppression
of retinal neovascularization in vivo by inhibition of vas-
cular endothelial growth factor (VEGF) using soluble
VEGF-receptor chimeric proteins. Proc Natl Acad Sci
USA. 1995; 92: 10457–61.
92. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E,
Okamoto N, Hofmann F, Wood JM, Campochiaro
PA. Blockade of vascular endothelial cell growth factor
receptor signaling is sufficient to completely prevent
retinal neovascularization. Am J Pathol. 2000; 156:
697–707.
93. Xia Y-P, Li B, Hylton D, Detmar M, Yancopoulos GD,
Rudge JS. Transgenic delivery of VEGF to mouse skin
leads to an inflammatory condition resembling human
psoriasis. Blood 2003; 102: 161–8.
94. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O,
Jackman RW, Berse B, Dvorak HF. Overexpression of
vascular permeability factor/vascular endothelial growth
factor and its receptors in psoriasis. J Exp Med. 1994;
180: 1141–6.
95. Folkman J. Tumor angiogenesis: therapeutic implica-
tions. N Engl J Med. 1971; 285: 1182–6.
96. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K,
Imazawa T, Taniguchi T, Tominaga T. Quantitative
analysis of vascular endothelial growth factor in primary
breast cancer. Cancer 1996; 77: 1101–6.
97. Toi M, Hoshina S, Takayanagi T, Tominaga T.
Association of vascular endothelial growth factor expres-
sion with tumor angiogenesis and with early relapse in
primary breast cancer. Jpn J Cancer Res. 1994; 85:
1045–9.
98. Hanahan D, Folkman J. Patterns and emerging mecha-
nisms of the angiogenic switch during tumorigenesis.
Cell 1996; 86: 353–64.
99. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of
angiogenesis. Cancer Res. 2005; 65: 3967–79.
100. Gerber HP, Malik AK, Solar GP, Sherman D, Liang
XH, Meng G, Hong K, Marsters JC, Ferrara N. VEGF
regulates haematopoietic stem cell survival by an internal
autocrine loop mechanism. Nature 2002; 417: 954–8.
101. Brusselmans K, Bono F, Collen D, Herbert JM,
Carmeliet P, Dewerchin M. A novel role for vascular
endothelial growth factor as an autocrine survival factor
for embryonic stem cells during hypoxia. J Biol Chem.
2005; 280: 3493–9.
102. Nor JE, Christensen J, Mooney DJ, Polverini PJ.
Vascular endothelial growth factor (VEGF)-mediated
angiogenesis is associated with enhanced endothelial cell
survival and induction of Bcl-2 expression. Am J Pathol.
1999; 154: 375–84.
103. Harmey JH, Bouchier-Hayes D. Vascular endothelial
growth factor (VEGF), a survival factor for tumour cells:
implications for anti-angiogenic therapy. Bioessays 2002;
24: 280–3.
104. Pidgeon GP, Barr MP, Harmey JH, Foley DA,
Bouchier-Hayes DJ. Vascular endothelial growth factor
(VEGF) upregulates BCL-2 and inhibits apoptosis in
human and murine mammary adenocarcinoma cells. Br J
Cancer 2001; 85: 273–8.
105. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L,
Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S.
Inhibition of both paracrine and autocrine VEGF/
VEGFR-2 signaling pathways is essential to induce long-
term remission of xenotransplanted human leukemias,
Proc Natl Acad Sci USA. 2001; 98: 10857–62.
106. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP,
Mauceri HJ, Salloum RM, Seetharam S, Koons A,
Hari DM, Kufe DW, Weichselbaum RR. Blockage of
the vascular endothelial growth factor stress response
increases the antitumor effects of ionizing radiation.
Cancer Res. 1999; 59: 3374–8.
107. Levy AP, Levy NS, Goldberg MA. Post-transcriptional
regulation of vascular endothelial growth factor by
hypoxia. J Biol Chem. 1996; 271: 2746–53.
108. Scott PA, Gleadle JM, Bicknell R, Harris AL. Role of
the hypoxia sensing system, acidity and reproductive hor-
mones in the variability of vascular endothelial growth
factor induction in human breast carcinoma cell lines. Int
J Cancer. 1998; 75: 706–12.
109. Riedel F, Gotte K, Goessler U, Sadick H, Hormann K.
Targeting chemotherapy-induced VEGF up-regulation by
VEGF antisense oligonucleotides in HNSCC cell lines,
Anticancer Res. 2004; 24: 2179–83.
110. Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara
K, Kobayashi M, Hirata S, Watanabe H. Vascular
endothelial growth factor inhibits apoptotic death in
793
J. Cell. Mol. Med. Vol 9, No 4, 2005
hematopoietic cells after exposure to chemotherapeutic
drugs by inducing MCL1 acting as an antiapoptotic fac-
tor. Cancer Res. 1998; 58: 5565–9.
111. Le Gouill S, Podar K, Amiot M, Hideshima T,
Chauhan D, Ishitsuka K, Kumar S, Raje N,
Richardson PG, Harousseau JL, Anderson KC. VEGF
induces Mcl-1 up-regulation and protects multiple myelo-
ma cells against apoptosis. Blood 2004; 104: 2886–92.
112. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel
RS. A role for survivin in chemoresistance of endothelial
cells mediated by VEGF. Proc Natl Acad Sci USA. 2002;
99: 4349–54.
113. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N,
Oltersdorf T, Reed JC. IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas
(CD95), Bax, caspases, and anticancer drugs. Cancer
Res. 1998; 58: 5315–20.
114. Giaccia AJ. Hypoxic stress proteins: survival of the Fit
test. Semin Radiat Oncol. 1996; 6: 46–58.
115. Shannon AM, Bouchier-Hayes DJ, Condron CM,
Toomey D. Tumour hypoxia, chemotherapeutic resis-
tance and hypoxia-related therapies. Cancer Treat Rev.
2003; 29: 297–307.
116. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE.
Response of tumour cells to hypoxia: role of p53 and
NFκB. Mol Pathol. 1998; 51: 55–61.
117. Comerford KM, Wallace TJ, Karhausen J, Louis NA,
Montalto MC, Colgan SP. Hypoxia-inducible factor-1-
dependent regulation of the multidrug resistance (MDR1)
gene. Cancer Res. 2002; 62: 3387–94. 
118. Harrison L, Blackwell K. Hypoxia and anemia: factors
in decreased sensitivity to radiation therapy and
chemotherapy? Oncologist 2004; 9: 31–40.
119. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W,
Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a
target for combined modality treatments. Eur J Cancer
2002; 38: 240–57.
120. Vaupel P. The role of hypoxia-induced factors in tumor
progression. Oncologist 2004; 9: 10–7.
121. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic sta-
bilization of vascular endothelial growth factor mRNA by
the RNA-binding protein HuR. J Biol Chem. 1998; 273:
6417–23.
122. Netti PA, Hamberg LM, Babich JW, Kierstead D,
Graham W, Hunter GJ, Wolf GL, Fischman A,
Boucher Y, Jain RK. Enhancement of fluid filtration
across tumor vessels: Implication for delivery of macro-
molecules. Proc Natl Acad Sci USA. 1999; 96: 3137–42.
123. Bergsland EK. Update on clinical trials targeting vascu-
lar endothelial growth factor in cancer. Am J Health Syst
Pharm. 2004; 61: S12–20.
124. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli
H, Klagsbrun M. Inhibition of vascular endothelial
growth factor (VEGF)-induced endothelial cell prolifera-
tion by a peptide corresponding to the exon 7-encoded
domain of VEGF165. J Biol Chem. 1997; 272: 31582–8.
125. Krause S, Forster Y, Kraemer K, Fuessel S, Kotzsch
M, Schmidt U, Wirth MP, Meye A, Schwenzer B.
Vascular endothelial growth factor antisense pretreatment
of bladder cancer cells significantly enhances the cyto-
toxicity of mitomycin C, gemcitabine and cisplatin. J
Urol. 2005; 174: 328–31.
126. Jain RK. Normalization of tumor vasculature: an
emerging concept in antiangiogenic therapy. Science
2005; 307: 58–62.
127. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G,
Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain
RK, Suit HD, Boucher Y. Anti-vascular endothelial
growth factor treatment augments tumor radiation
response under normoxic or hypoxic conditions.
Cancer Res. 2000; 60: 5565–70.
128. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz
HI, Bergsland E, Sarkar S. Combined analysis of
efficacy: The addition of bevacizumab to fluo-
rouracil/leucovorin improves survival for patients
with metastatic colorectal cancer. J Clin Oncol. 2005;
23: 3706–12.
129. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M,
Ruijter R, Huisman H, Kedde MA, Noordhuis P,
van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P,
Hoekman K, Pinedo HM, Giaccone G. Dose-finding
and pharmacokinetic study of cisplatin, gemcitabine,
and SU5416 in patients with solid tumors. J Clin
Oncol. 2002; 20: 1657–67.
130. Kerbel RS, Kamen BA. The anti-angiogenic basis of
metronomic chemotherapy. Nat Rev Cancer 2004; 4:
423–36.
131. Hanahan D, Bergers G, Bergsland E. Less is more,
regularly: metronomic dosing of cytotoxic drugs can
target tumor angiogenesis in mice. J Clin Invest. 2000;
105: 1045–7.
132. Monestiroli S, Mancuso P, Burlini A, Pruneri G,
Dell’Agnola C, Gobbi A, Martinelli G, Bertolini F.
Kinetics and viability of circulating endothelial cells
as surrogate angiogenesis marker in an animal model
of human lymphoma. Cancer Res. 2001; 61: 4341–4.
133. Bertolini F, Paul S, Mancuso P, Monestiroli S,
Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable
dose and low-dose metronomic chemotherapy have
opposite effects on the mobilization and viability of
circulating endothelial progenitor cells. Cancer Res.
2003; 63: 4342–6.
134. Bocci G, Francia G, Man S, Lawler J, Kerbel RS.
Thrombospondin 1, a mediator of the antiangiogenic
effects of low-dose metronomic chemotherapy. Proc
Natl Acad Sci USA. 2003; 100: 12917–22.
135. Klement G, Huang P, Mayer B, Green SK, Man S,
Bohlen P, Hicklin D, Kerbel RS. Differences in ther-
apeutic indexes of combination metronomic
chemotherapy and an anti-VEGFR-2 antibody in mul-
tidrug-resistant human breast cancer xenografts. Clin
Cancer Res. 2002; 8: 221–32.
794
